Clinical trial
Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors
NCT00004923 · Yale University, Other · Completed
Key facts
| NCT number | NCT00004923 |
|---|---|
| Title | Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors |
| Official title | Dose Escalation Trial of Docetaxel Plus Irinotecan in Patients With Advanced Cancer |
| Lead sponsor | Yale University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | docetaxel, irinotecan hydrochloride |
| Enrollment | 47 |
| Start date | Apr 1, 1999 |
| Completion | May 1, 2006 |
| First posted | Apr 28, 2004 |
| Last update posted | Aug 25, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: